Protagonist Therapeutics, Inc.
US ˙ NasdaqGM ˙ US74366E1029

SecurityPTGX / Protagonist Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership508,103 shares
Latest Disclosed Value $ 53,541,525
Dimensional Fund Advisors Lp reports 22.61% increase in ownership of PTGX / Protagonist Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 508,103 shares of Protagonist Therapeutics, Inc. (US:PTGX) valued at $53,554,056 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 414,415 shares of Protagonist Therapeutics, Inc.. This represents a change in shares of 22.61% during the quarter. The current value of the position is $49,479,070 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 508,103 93,688 22.61 53,542 47.93 0.0024
2026-02-12 2025-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 414,415 -24,100 -5.50 36,195 24.26 0.0076
2025-11-12 2025-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 438,515 258,465 143.55 29,127 192.67 0.0063
2025-08-12 2025-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 180,050 58,496 48.12 9,952 69.31 0.0023
2025-05-13 2025-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 121,554 -104,046 -46.12 5,878 -32.50 0.0015
2025-02-13 2024-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 225,600 11 0.00 8,708 -14.22 0.0021
2024-11-07 2024-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 225,589 -390,583 -63.39 10,152 -52.44 0.0025
2024-08-09 2024-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 616,172 -175,172 -22.14 21,346 -6.76 0.0056
2024-05-10 2024-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 791,344 -25,193 -3.09 22,894 22.27 0.0062
2024-02-07 2023-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 816,537 -124,737 -13.25 18,724 19.25 0.0055
2023-11-09 2023-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 941,274 -97,831 -9.41 15,701 -45.29 0.0051
2023-08-09 2023-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,039,105 -223,154 -17.68 28,700 -1.14 0.0091
2023-05-12 2023-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,262,259 185,033 17.18 29,031 263,818.18 0.0098
2023-02-09 2022-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 1,077,226 256,788 31.30 12 -99.84 0.0035
2022-11-10 2022-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 820,438 -32,337 -3.79 6,916 2.54 0.0027
2022-08-12 2022-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 852,775 -10,117 -1.17 6,745 -66.99 0.0024
2022-05-13 2022-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 862,892 -11,759 -1.34 20,434 -31.69 0.0063
2022-02-09 2021-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 874,651 -1,081 -0.12 29,913 92.76 0.0090
2021-11-12 2021-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 875,732 84,716 10.71 15,518 -56.29 0.0050
2021-08-12 2021-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 791,016 134,915 20.56 35,499 109.08 0.0112
2021-05-14 2021-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 656,101 6,561 1.01 16,979 29.66 0.0056
2021-03-08 2020-12-31 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 649,540 -35,716 -5.21 13,095 -2.25 0.0047
2021-02-11 2020-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 649,540 -35,716 13,095 4,729.2180
2020-11-12 2020-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 685,256 -1,641 -0.24 13,397 10.45 0.0057
2020-08-13 2020-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 686,897 13,249 1.97 12,130 155.05 0.0053
2020-05-14 2020-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 673,648 2,897 0.43 4,756 0.57 0.0025
2020-02-14 2019-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 670,751 -60,554 -8.28 4,729 -46.16 0.0017
2019-11-12 2019-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 731,305 -12,753 -1.71 8,784 -2.51 0.0034
2019-08-13 2019-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 744,058 80,281 12.09 9,010 7.99 0.0035
2019-08-12 2019-03-31 13F/A-2 PROTAGONIST THERAPEUTICS COM 74366E102 663,777 173,510 35.39 8,343 152.89 0.0033
2019-05-10 2019-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 663,777 173,510 8,343
2019-02-26 2018-12-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 490,267 122,250 33.22 3,299 -12.89 0.0015
2019-02-13 2018-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 490,267 122,250 3,299
2018-11-13 2018-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 368,017 140,200 61.54 3,787 147.35 0.0014
2018-08-10 2018-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 227,817 227,817 1,531 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.